Insmed Incorporated

As of June 30, 2026, Insmed Incorporated carries a market capitalization of 413.64B, placing it among publicly traded companies globally. Its enterprise value stands at 403.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Insmed Incorporated's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Insmed Incorporated has 218.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 20.46, and the price-to-book ratio stands at 31.25.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 403.50B versus a market cap of 413.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Insmed Incorporated maintains a current ratio of 3.72, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.55, indicating elevated leverage, while an interest coverage ratio of -10.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Insmed Incorporated posted a negative return on equity (ROE) of -87.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.20, reflecting losses generated across the asset base. The company generates approximately 12.69M in revenue per employee across its workforce of 1,565.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.51 indicates how many times Insmed Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Insmed Incorporated recorded 108.41M in income tax expense. The company reported a pretax loss of -15.18B and -15.29B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Insmed Incorporated generated 19.88B in revenue and converted that into -15.29B in net income, yielding earnings per share of -71.28. EBITDA reached -14.34B, while operating income came in at -14.20B.

As of June 30, 2026, Insmed Incorporated holds 20.27B in cash and equivalents against 10.13B in total debt, resulting in a net debt position of -21.87M. Total book value stands at 13.23B, with working capital of 20.88B providing operational flexibility.

Insmed Incorporated produced -13.61B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -502.24M in capital expenditures, free cash flow totaled -14.11B - equivalent to -65.77 per share.

Over the twelve months ended June 30, 2026, Insmed Incorporated posted a gross margin of 83.46, reflecting its pricing power and cost economics. The operating margin of -71.43 and net profit margin of -76.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.52, meaning Insmed Incorporated raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Insmed Incorporated's most recent stock split took place on March 3, 2011 with a 10:1 split ratio.

As of June 30, 2026, Insmed Incorporated has an Altman Z-Score of 6.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.